Epidemiology of uveal melanomas in Moscow

Cover Page


Cite item

Full Text

Abstract

Rationale: Melanoma of the uveal tract of the eye is among the most prevalent malignant intraocular tumors.

Aim: To identify epidemiological characteristics of uveal melanoma in Moscow.

Materials and methods: We performed a retrospective analysis of out-patient files and follow-up charts of patients with uveal melanoma in the Ophthalmological Clinical Hospital of the Department of Healthcare, Moscow, from 1977 to 2012.

Results: Within 36 years, 2547 patients with uveal melanoma have been registered, at the age of 16 to 92 years. The male to female ratio was 1:1.5. The rate of patient referrals with subsequent diagnosis of uveal melanoma has not changed from 1977 to 2000 and was on average 1.07 persons per 100,000 of the adult population. From 2001 to 2012, there was some decline in the number of referrals with uveal melanoma to the average of 0.9 persons per 100,000 of the adult population. We analyzed survival among 359 patients with uveal melanoma after enucleation surgery of the eye; 37% of them were men (63.2 ± 1.8 years) and 63% women (69.5 ± 2.7 years). Their 5-year metastasis-free survival was 65 ± 3%, whereas the 7-year survival was 60 ± 4%. The mean time to death was 5.5 years. There were no association between the life longevity and patients gender, but their survival was associated with the age of patients. The risk of death from metastatic uveal melanoma among patients above 60 years of age was on average 10% higher. After the enucleation surgery, patients with Т4 melanoma lived significantly less than those with Т1-3 tumor (5 and 6.5 years, respectively; р = 0.05).

Conclusion: The rates of diagnosis of uveal melanoma at referrals within 36 years did not increased. Epidemiology of uveal melanoma in Moscow is characterized by a high proportion of elderly women. Shorter overall and metastasis-free survival of patients with uveal melanoma after the enucleation surgery depends from a higher proportion of elderly people in the regional population and late diagnosis of the disease.

About the authors

E. E. Grishina

Moscow Regional Research and Clinical Institute (MONIKI)

Author for correspondence.
Email: eyelena@mail.ru

MD, PhD, Professor, Leading Research Fellow, Ophthalmology Department

61/2–11 Shchepkina ul., Moscow, 129110, Russian Federation. Tel.: +7 (905) 703 18 63.

Russian Federation

M. Yu. Lerner

City Clinical Hospital named after S.P. Botkin (Moscow), Branch No. 1, Ophthalmological Hospital

Email: fake@neicon.ru

MD, PhD, Director of the Moscow Municipal Center of Ophthalmic Oncology

7 Mamonovskiy pereulok, Moscow, 123001, Russian Federation

Russian Federation

E. G. Gemdzhian

National Research Center for Hematology

Email: fake@neicon.ru

Senior Research Fellow, Biostatistics Laboratory

4 Novyy Zykovskiy proezd, Moscow, 125167, Russian Federation

Russian Federation

References

  1. McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103(5): 1000–7. doi: 10.1002/cncr.20866.
  2. Бровкина АФ, ред. Офтальмоонкология. М.: Медицина; 2002. 424 с.
  3. Damato B. Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture. Eye (Lond). 2012;26(9): 1157–72. doi: 10.1038/eye.2012.126.
  4. Гришина ЕЕ, Давыдов ДВ, Стоюхина АС. Энуклеации при увеальной меланоме (анализ архивного материала). Вестник офтальмологии. 2010;126(2): 30–4.
  5. Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, Lutz JM, Paci E; EUROCARE Working Group. Incidence of uveal melanoma in Europe. Ophthalmology. 2007;114(12): 2309–15. doi: 10.1016/j.ophtha.2007.01.032.
  6. Park SJ, Oh CM, Kim BW, Woo SJ, Cho H, Park KH. Nationwide Incidence of Ocular Melanoma in South Korea by Using the National Cancer Registry Database (1999-2011). Invest Ophthalmol Vis Sci. 2015;56(8): 4719–24. doi: 10.1167/iovs.15-16532.
  7. Shields CL, Kels JG, Shields JA. Melanoma of the eye: revealing hidden secrets, one at a time. Clin Dermatol. 2015;33(2): 183–96. doi: 10.1016/j.clindermatol.2014.10.010.
  8. Damato EM, Damato BE. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients. Ophthalmology. 2012;119(8): 1582–9. doi: 10.1016/j.ophtha.2012.01.048.
  9. Andreoli MT, Mieler WF, Leiderman YI. Epidemiological trends in uveal melanoma. Br J Ophthalmol. 2015;99(11): 1550–3. doi: 10.1136/bjophthalmol-2015-306810.
  10. Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, Lutz JM, Paci E; EUROCARE Working Group. Survival in patients with uveal melanoma in Europe. Arch Ophthalmol. 2008;126(10): 1413–8. doi: 10.1001/archopht.126.10.1413.
  11. Саакян СВ, Пантелеева ОГ, Ширина ТВ. Оценка выживаемости больных увеальной меланомой после органосохранного лечения и энуклеации. Российский офтальмологический журнал. 2011;(1): 67–70.
  12. Abrams MJ, Gagne NL, Melhus CS, Mignano JE. Brachytherapy vs. external beam radiotherapy for choroidal melanoma: Survival and patternsof- care analyses. Brachytherapy. 2016;15(2): 216–23. doi: 10.1016/j.brachy.2015.12.001.
  13. Liu YM, Li Y, Wei WB, Xu X, Jonas JB. Clinical Characteristics of 582 Patients with Uveal Melanoma in China. PLoS One. 2015;10(12):e0144562. doi: 10.1371/journal.pone.0144562.
  14. Sagus M, Bedikian AY. Uveal melanoma in the first 4 decades of life. South Med J. 2015;108(3): 158–63. doi: 10.14423/SMJ.0000000000000248.
  15. Jancar B, Budihna M, Drnovsek-Olup B, Andrejcic KN, Zupancic IB, Pahor D. Prognostic factors of choroidal melanoma in Slovenia, 1986–2008. Radiol Oncol. 2016;50(1): 104–12. doi: 10.1515/raon-2015-0009.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2017 Grishina E.E., Lerner M.Y., Gemdzhian E.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies